|Day Low/High||1.18 / 1.24|
|52 Wk Low/High||0.83 / 5.75|
Khang & Khang LLP (the "Firm") announces that it is investigating claims against Alcobra, Ltd.
Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Alcobra, Ltd.
Goldberg Law PC announces that it is investigating Alcobra Ltd.
Levi & Korsinsky announces it has commenced an investigation of Alcobra Ltd.
Alcobra has plans to restore shareholder value, but it's unclear what that plan will entail.
Management to hold a conference call & webcast today, January 17th at 8:00 a.m. EST
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
Alcobra (ADHD) stock rating was reduced to 'neutral' at Piper Jaffray on Friday.
Alcobra (ADHD) announced late yesterday that the FDA has placed a clinical hold on its new drug applications for MDX for ADHD treatment.
Conference Call & Webcast August 30th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.